Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) Just Reported Decreased Shorts

February 15, 2018 - By Kurt Siggers

 Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) Just Reported Decreased Shorts

Investors sentiment decreased to 0 in Q3 2017. Its down 0.88, from 0.88 in 2017Q2. It dropped, as 101 investors sold Merrimack Pharmaceuticals, Inc. shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 2.91 million shares or 95.42% less from 63.69 million shares in 2017Q2 were reported.
Ameritas Inv has 0% invested in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK). 50 are held by Horrell Incorporated. Dekabank Deutsche Girozentrale holds 27,500 shares. 2.88 million are owned by Putnam Investments Ltd.

Since September 11, 2017, it had 0 insider purchases, and 2 insider sales for $422,765 activity.

The stock of Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) registered a decrease of 0.38% in short interest. MACK’s total short interest was 1.98M shares in February as published by FINRA. Its down 0.38% from 1.99 million shares, reported previously. With 155,400 shares average volume, it will take short sellers 13 days to cover their MACK’s short positions.

The stock increased 1.81% or $0.19 during the last trading session, reaching $10.68. About 59,644 shares traded. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has declined 44.78% since February 15, 2017 and is downtrending. It has underperformed by 61.48% the S&P500.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $142.46 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.31 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Ratings Coverage

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Mizuho on Wednesday, December 23. The firm has “Neutral” rating given on Friday, May 27 by Robert W. Baird. The rating was reinitiated by Oppenheimer on Wednesday, August 12 with “Outperform”. The rating was maintained by Robert W. Baird with “Hold” on Monday, September 11. The stock of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has “Neutral” rating given on Friday, October 7 by JP Morgan. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. Mizuho maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) rating on Wednesday, August 12. Mizuho has “Outperform” rating and $16 target. BTIG Research initiated Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Friday, August 19 with “Neutral” rating. The rating was maintained by Oppenheimer on Tuesday, October 27 with “Outperform”. The rating was maintained by Robert W. Baird with “Hold” on Friday, October 13.

More important recent Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news were published by: Bostonglobe.com which released: “Merrimack Pharmaceuticals paying shareholders $140 million special dividend” on April 05, 2017, also Prnewswire.com published article titled: “Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference”, Prnewswire.com published: “Merrimack Announces Appointment of George Demetri, MD, to Board of Directors” on November 30, 2017. More interesting news about Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) was released by: Nasdaq.com and their article: “Merrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017” with publication date: May 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.